| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $20.0M | -6.4% | -6.4% |
| SG&A Expense | $6.0M | +4.7% | +37.3% |
| Operating Income | -$26.0M | +4.0% | -1.0% |
| Net Income | -$25.6M | +4.6% | -5.0% |
| EPS (Basic) | -$0.13 | +35.0% | +45.8% |
| EPS (Diluted) | -$0.13 | +35.0% | +45.8% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $35.1M | -36.5% | -40.5% |
| Current Assets | $39.3M | -34.4% | -37.9% |
| Total Assets | $40.7M | -33.7% | -37.1% |
| Current Liabilities | $30.1M | +10.1% | +28.8% |
| Total Liabilities | $30.2M | +9.8% | +28.3% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$66.5M | — | — |
| Capital Expenditures | $150K | — | — |
| Investing Cash Flow | -$150K | — | — |
| Financing Cash Flow | $65.5M | — | — |
| Free Cash Flow | -$66.7M | — | — |
| $10.5M |
| -69.0% |
| -74.5% |